Alembic Pharmaceuticals Ltd

* USFDA approval received: Alembic Pharmaceuticals has received final USFDA approval for Oseltamivir Phosphate for Oral Suspension, an antiviral generic used to treat and prevent influenza, strengthening its U.S. generics portfolio. * Commercial significance: The approved product addresses a U.S. market with annual sales of approximately US$27 million (IQVIA), providing Alembic with an opportunity to expand its U.S. revenues, although the market size is relatively modest and revenue potential will depend on competition and market share gains.